SuperworthIonis Pharmaceuticals EPS IONS
Diluted earnings per share by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jun 30, 2026
- −$3.46
- Latest quarter, Q2 FY26
- −$0.69
- −199% on a year earlier
- Fiscal year 2025
- −$2.44
Ionis Pharmaceuticals' earnings per share was −$3.46 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.69, down 199% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$2.44 | n/a |
| FY2024 | −$3.04 | n/a |
| FY2023 | −$2.56 | n/a |
| FY2022 | −$1.90 | n/a |
| FY2021 | −$0.20 | n/a |
| FY2020 | −$3.17 | −253% |
| FY2019 | $2.07 | +10% |
| FY2018 | $1.88 | +3660% |
| FY2017 | $0.05 | n/a |
| FY2016 | −$0.72 | n/a |
| FY2015 | −$0.74 | n/a |
| FY2014 | −$0.34 | n/a |
| FY2013 | −$0.53 | n/a |
| FY2012 | −$0.65 | n/a |
| FY2011 | −$0.85 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.69 | −199% | −$3.46 | |
| Q1 FY26 | −$0.56 | n/a | −$2.07 | |
| Q4 FY25 | −$1.41 | n/a | −$2.44 | |
| Q3 FY25 | −$0.80 | n/a | −$1.69 | |
| Q2 FY25 | $0.70 | n/a | −$1.84 | |
| Q1 FY25 | −$0.93 | n/a | −$2.99 | |
| Q4 FY24 | −$0.66 | n/a | −$3.04 | |
| Q3 FY24 | −$0.95 | n/a | −$2.44 | |
| Q2 FY24 | −$0.45 | n/a | −$2.52 | |
| Q1 FY24 | −$0.98 | n/a | −$2.67 | |
| Q4 FY23 | −$0.06 | n/a | −$2.56 | |
| Q3 FY23 | −$1.03 | n/a | −$2.87 |
Against its peers
Companies in Drug Manufacturers - General nearest Ionis Pharmaceuticals' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| IONSIonis Pharmaceuticals | −$3.46 | |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $0.73 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ionis Pharmaceuticals
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.